We can't find the internet
Attempting to reconnect
17388.2 PFLS-LS
17388.2 PFLS-LS
Résumé
Design and Validation of new TLR agonists for therapeutic vaccination in oncology
Textes supplémentaires
Abstract
Modulating the cancer patient own immune system, to allow the specificdestruction of the tumoral cells, is becoming an attractive approach in oncology. This can be achieved through therapeutic cancer vaccines. One essential component to mount an efficacious anti-tumor immunity are adjuvants. Toll Like Receptor (TLR) agonists have risen recently as promising adjuvants of cancer vaccines. The goal of this project is to design and validate novel peptide agonist of TLR .
Participants
Madiha Derouazi
Wirtschaftspartner
madiha.derouazi@amaltherapeutics.com
Amal Therapeutics SA Madiha Derouazi Avenue de la Roseraie 64 1205 Genève GE CH
Vincent Zoete
Kontaktperson
Swiss Institute of Bioformatics (SI Vincent Zoete Bâtiment Genopode / Quartier Sorge 1015 Lausanne VD CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2014-12-31
- Date de fin
- 2016-12-31
- Coûts totaux approuvés
- CHF 554750.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%